DocuSign Inc DOCU is among the “have nots” in the tech sector and may continue to see its multiplies compress “as results soften off pandemic highs,” according to Wedbush.
The DocuSign Analyst: Daniel Ives downgraded the rating for DocuSign from Neutral to Underperform, while reducing the price target from $80 to $60.
The DocuSign Thesis: Although DocuSign benefited significantly from the adoption of the work-from-home model by most companies during the pandemic, the company will see “darker days ahead” as it expands into larger (contract lifecycle management) deals, Ives said in the downgrade note.
Also Read: If You Invested $1,000 In The Short Cathie Wood ETF At IPO, Here's How Much You'd Have Now
DocuSign is up against “a much more difficult selling environment as the company expands into broader CLM deals with e-signature going through a major growth transition in the field,” he added.
The analyst mentioned that DocuSign’s hypergrowth story may be “essentially over” and the company “could see difficult growth ahead not factored into shares at current prices in our opinion.”
DOCU Price Action: Shares of DocuSign had declined by 2.20% to $83.94 at the time of publication Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.